RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch Rob Jackson joins as Vice President of MarketingRobert J. Gilkin, Jr. joins as Vice President of Market AccessSteven Thomasian to join as Vice President of Supply Chain TEL-AVIV, Israel and RALEIGH,...

RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint, with top-line results...

Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA™ and support the European marketing application...

RedHill Biopharma Announces Full Exercise of Underwriters' Over-Allotment Option TEL-AVIV, Israel, Feb. 18, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...

Pressure BioSciences, Inc. to Discuss Third Quarter 2011 Financial Results and Provide Business Update SOUTH EASTON, Mass., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its...